ITL Health Group (“ITL”), a manufacturer and seller of medical technology to the global blood market and consumer pathology test provider, is pleased to announce results for the half year ended 31 December 2017.
Read More “ITL Health Group Announces Half Year 2017/18 Results”
ITL Health Group (ASX:ITD), is pleased to announce that its wholly owned subsidiary MyHealthTest Pty Ltd (MHT), the direct to consumer pathology test provider, has launched a prostate specific antigen (PSA) test service to help men who wish to monitor their PSA level from home. The test means MHT is now marketing four test services to total addressable markets in excess of $1bn.
ITL Health Group (ASX:ITD), is pleased to announce that its wholly owned subsidiary MyHealthTest Pty Ltd (MHT), the direct to consumer pathology test provider, has launched a cholesterol test service to assist with the management of this very serious health risk.
ITL Health Group (ASX:ITD) is pleased to announce that its wholly owned subsidiary MyHealthTest Pty Ltd (MHT), the direct to consumer pathology test provider, has launched a Thyroid TSH Test Service, with immediate effect.
ITL Health Group (ASX:ITD) is pleased to announce the launch of ITL BioMedical’s latest blood culture testing product, the Transfer Cap Set.
The Transfer Cap Set is a product used to transfer positive culture samples from a bacterial collection bottle to a vacuum tube safely and efficiently. The product is designed for use in hospital laboratories that automate smearing samples from positive bacterial detection bottles.
Read More “ITL BioMedical Launches New Blood Culture Testing Product”
ITL BioMedical, a division of ITL Health Group (ASX:ITD), that creates and manufacturers leading edge medical devices for the clinical, blood banking and laboratory markets, is pleased to announce the launch of a new global brand, ITL Clinical, that will feature ITL products that serve the hospital and clinical markets.
Boardroom Media Interview
ITL Health Group (ASX:ITD) is pleased to provide the opportunity to listen to an audio interview with Mr. Bill Mobbs, Executive Chairman.
Read More “Audio Interview with Bill Mobbs discussing Strategy and Expectations”
ITL Health Group (ASX:ITD), an innovative global medical technology company is pleased to announce that Melbourne based Henslow have initiated coverage on ITL Health Group.
ITL Health Group (ASX:ITD), an innovative global medical technology company, is pleased to announce the sale of its Australian Custom Pack business unit, part of the ITL Healthcare division, to Nasdaq-listed multi-national Merit Medical Systems, Inc. (“Merit”) for $14.4m (“Sale”). The Sale was signed and completed on 2nd October 2017.
